Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | FDPS | P14324 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | C5 | P01031 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PPIA | P62937 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1956731 | 0.93 | LMNA (0.43) | LMNATHRATHRBFDPSTLR8 | |
| SCHEMBL5073881 | 0.85 | THRA (0.47) | LMNATHRATHRBTLR8ALOX5 | |
| SCHEMBL6248953 | 0.83 | LMNA (0.37) | LMNATHRATHRBFDPSTLR8 | |
| SCHEMBL2906169 | 0.83 | LMNA (0.37) | LMNATHRATHRBFDPSTLR8 | |
| SCHEMBL27490530 | 0.82 | HTR7 (0.49) | LMNATLR8ALOX5HTTTDP1 | |
| SCHEMBL13016850 | 0.81 | LMNA (0.45) | LMNAFDPSTLR8ALOX5GGPS1 | |
| SCHEMBL11957249 | 0.80 | HTR2A (0.37) | LMNATDP1 | |
| SCHEMBL4563654 | 0.80 | LMNA (0.37) | LMNATHRATHRBFDPSTLR8 | |
| SCHEMBL13342512 | 0.79 | LMNA (0.34) | LMNATHRATHRBFDPSTLR8 | |
| SCHEMBL1954221 | 0.79 | APP (0.38) | LMNAFDPSTLR8ALOX5GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120323164-A1 | PHOTODYNAMIC THERAPY WITH PHTHALOCYANINES AND RADICAL SOURCES | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120323164-A1 | PHOTODYNAMIC THERAPY WITH PHTHALOCYANINES AND RADICAL SOURCES | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120323164-A1 | PHOTODYNAMIC THERAPY WITH PHTHALOCYANINES AND RADICAL SOURCES | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323164-A1 | PHOTODYNAMIC THERAPY WITH PHTHALOCYANINES AND RADICAL SOURCES | PPOX, COXFA4L2, ALDH1A2 | LMNA 3624/4885THRA 2836/4885THRB 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.